In preclinical and clinical trials of albumin, intravenous infusion of medium and high doses of 25% human serum albumin solution demonstrates a neuroprotective effect in AIS which increases with increasing doses up to 2.05 g/kg (35). The gene discussed is ALB; the disease is androgen insensitivity syndrome.